Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;46(3):480-486.
doi: 10.1111/ced.14537. Epub 2021 Feb 4.

News on infantile haemangioma. Part 2: therapy and evaluation

J Saerens  1 , H De Leye  1 , S R Janmohamed  1
Affiliations
Review

News on infantile haemangioma. Part 2: therapy and evaluation

J Saerens et al. Clin Exp Dermatol. 2021 Apr.

Abstract

Infantile haemangioma (IH) is the most frequently occurring tumour of childhood. While benign, in more than half of the cases, less or more severe sequelae can be observed. In Part 1 of this review, we discussed the clinical course and pathomechanism of IHs. In Part 2 of this state-of-the-art review, we will discuss the current management of IH and focus on the working mechanism of β-blockers in IHs. Furthermore, we will discuss options for the evaluation of patients and their families (quality of life and family burden), as well as for the evaluation of IHs by healthcare providers, such as assessments of activity and severity. This review will update the reader on the working mechanism of propranolol in IHs and offer an oversight of tools (questionnaires and scoring systems) that can be used in clinical practice or for research.

PubMed Disclaimer

References

    1. Novoa M, Baselga E, Beltran S et al. Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev 2018; 4: CD006545.
    1. Hoeger PH, Harper JI, Baselga E et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr 2015; 174: 855-65.
    1. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-51.
    1. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735-46.
    1. Wedgeworth E, Glover M, Irvine AD et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. Br J Dermatol 2016; 174: 594-601.